Gossamer Bio Submits FDA New Drug Application for Seralutinib in PAH

Key Facts

1Gossamer Bio submitted a New Drug Application (NDA) to the U.S. FDA for seralutinib.

2The drug candidate seralutinib is intended for the treatment of pulmonary arterial hypertension (PAH).

In a move reflecting the accelerating pace of innovation within the biotechnology sector, Gossamer Bio has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). The application seeks approval for seralutinib, a therapeutic candidate specifically designed for patients suffering from pulmonary arterial hypertension (PAH). This submission marks a strategic pivot for the company, moving from clinical-stage development toward a commercialization path following the completion of necessary clinical phases.

This development comes as the healthcare sector continues to prioritize advanced therapeutic solutions for rare and chronic conditions. Per market data, GOSS shares closed at $11.69 (close September 22, 2026), having traded between a day high of $12.31 and a day low of $11.35 during that session. The formal NDA submission is viewed as a significant de-risking milestone for clinical-stage biotech firms, although final FDA acceptance and approval remain pending.

Looking ahead, investors are awaiting the FDA's formal acceptance of the application and the commencement of the review process, which will dictate the potential launch timeline. Based on pre-fetched data, GOSS was priced at $11.69 at the close of September 22, 2026. While there are no immediate upcoming corporate events in the calendar, market attention remains fixed on regulatory updates regarding the approval trajectory of seralutinib.